May 30, 2024 -
Toronto, CANADA – May 30th, 2024 – MolecuLight Inc., the global leader in fluorescence imaging technology for real-time detection of harmful bacteria in wound care, celebrates the publication of a groundbreaking study in the prestigious Burns Journal. Titled “Bacterial Fluorescence Imaging as a Predictor
… Read MoreMay 2, 2024 -Wide-Spread Clinical Evidence using the MolecuLight Imaging Platform Reveals its Significant Global Adoption and Proven Utility in Wound Care
Toronto, CANADA and London, UK – (May 1, 2024) – MolecuLight Corp., the leader in point-of-care digital wound measurement and real-time bacterial detection through fluorescence imaging, announces that its MolecuLight wound imaging
… Read MoreJanuary 25, 2024 -New Contract Expands VA Wound Care Center Access to MolecuLight i:X® and DX™ Point-of-Care Devices that Help Clinicians Manage Infection and Improve Outcomes
Pittsburgh, PA – January25, 2024 – MolecuLight Corp., the leader in point-of-care bacterial fluorescence imaging, announced today that the US Department of Veterans Affairs has awarded MolecuLight a
… Read MoreDecember 12, 2023 -The company’s compliance to SOC 2 Type II demonstrates the suitability of the design and operating effectiveness of its controls relevant to security
TORONTO, ON – (December 12, 2023) MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated bacterial loads in and around wounds, announces
… Read MoreNovember 21, 2023 -MolecuLight Victorious in its Efforts to Prove Swift Medical Did Not Merit a Patent
Toronto, ON, CANADA, and Alexandria, VA, USA – (November 21, 2023) MolecuLight® Inc., the leader in real-time detection of elevated bacterial loads in wounds through point-of-care fluorescence imaging, is pleased to announce the United States Patent
… Read MoreNovember 2, 2023 -Unprecedented Body of New Clinical Evidence using the MolecuLight Wound Imaging Platform Demonstrates Improved Clinical Decision-Making and Patient Outcomes
Toronto, CANADA and Las Vegas, NEVADA – (November 2, 2023) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, announces
… Read MoreSeptember 21, 2023 -6 Clinical Posters and a Presentation Including New Results of a 1,447 Patient Study Highlights the Breadth of Clinical Benefits of the MolecuLight Device for Wound Care Applications
Toronto, ONTARIO and Philadelphia, PENNSYLVANIA – (September 21, 2023) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of
… Read MoreJuly 6, 2023 -Former Healogics CEO Brings Deep Wound Care Industry Experience to MolecuLight’s Rapidly Growing Business
TORONTO, ON – (July 6, 2023) – MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated, pathogenic bacterial loads in and around wounds, is pleased to announce the appointment of David
… Read MoreMay 23, 2023 -Results from 211 Facilities Show MolecuLight Imaging is a Valuable Tool in Improving Bacterial Infection Management
TORONTO, ON – (May 23, 2023) MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated, pathogenic bacterial loads in and around wounds, announced the publication of their latest publication,
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2024
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.